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Scientific Abstracts to the application of the EMA recommendation (interaction p value=0.140). In the 59 pts not treated in accordance with the EMA recommendation, the treatment effect in the sub-groups of pts without (vs with) concomitant FM was 38% vs 40% respectively, p=0.891. In the 449 pts treated in accordance with the EMA recommendation, the treatment effect in the sub-groups of pts without (vs with) concomitant FM was 56% vs 46%, p=0.042).
Conclusions: This study suggests that 1/ French rheumatologists are applying the EMA recommendation in daily practice 2/ these recommendations result in a better outcome in terms of short term symptomatic treatment effect. In this study, concomitant FM was not more frequently observed in patients without (vs with) objective sign of structural damage or inflammation and the impact of a concomitant FM was not more pronounced (or even lower) in pts without (vs with) objective sign of structural damage or inflammation. Background: Nitric oxide (NO) regulates the synthesis of several inflammatory mediators, functions of inflammatory cells in the inflamed joint and plays a central role in the regulation of blood vessel tone 1 . Therefore, NO inhibitors represent important therapeutic advancement in the management of inflammatory diseases. Rosuvastatin improves NO and endothelial dysfunction in patients with heart failure 2 but its effect on NO has not yet been tested in Ankylosing Spondylitis (AS) patients. Objectives: To investigate the effect of rosuvastatin on nitrite levels (NO surrogate) and its relationship with endothelial function and inflammatory measures in AS. Methods: 40 consecutive patients (20 in Rosuvastatin (10 mg/day) and 20 in placebo arm) meeting the modified New York criteria for AS, with active disease despite treatment with conventional synthetic DMARDs were recruited. Serum nitrite estimation was carried out by Griess reaction. Flow-mediated dilatation (FMD) was assessed using AngioDefender. Inflammatory measures included-BASDAI, BASFI, ESR and CRP. Pro-inflammatory cytokines (TNF-α, IL-6 and IL-1) were measured at baseline and after 24 weeks. Results: After 24 weeks, significant improvement in serum nitrite was observed in rosuvastatin group (5.27±0.26 to 4.11±0.19, p<0.01) compared with placebo (5.47±0.26 to 5.36±0.23, p=0.33). At 24weeks; FMD, TNF-α, and IL-6 improved significantly in rosuvastatin group compared with placebo. At 24 weeks; ESR, CRP, BASDAI and BASFI significantly improved in rosuvastatin group compared with placebo. After treatment with rosuvastatin, nitrite correlated inversely with FMD (r=-0.47, p=0.03) (Fig.1A) and positively with TNF-α (r=0.64, p=0.01) (Fig.1B) , CRP (r=0.52, p=0.01) (Fig.1C) and LDL (r=0.54, p=0.01) (Fig.1D) .
Conclusions:
Rosuvastatin reduced serum nitrite concentration and improved endothelial dysfunction in AS patients. Rosuvastatin lowers the proinflammatory cytokines, especially IL-6 and TNF-α, which downregulates CRP production and thus the production of NO. Rosuvastatin also favorably improved the lipid levels in AS patients. Rosuvastatin exerts anti-inflammatory, immunomodulatory and vasculoprotective effect in ankylosing spondylitis through both cholesterol dependent and cholesterol independent pathways References: [ Objectives: To report long-term (up to 3 years) pooled safety and tolerability data for secukinumab in AS (data cut-off: 25 June 2016). Methods: Overall, 371, 219 and 226 patients with active AS were randomised in MEASURE 1, MEASURE 2 and MEASURE 3, respectively. Study design, efficacy and safety results of these studies have been published earlier.
1,2 Secukinumab doses differed in the studies and included intravenous 10 mg/kg or subcutaneous (75-300mg) multi-dose loading, followed by subcutaneous (s.c.) maintenance dosing (75, 150, or 300mg) . Data collected up to the last patient performing the Wk 156 visit in MEASURE 1, the Wk 104 visit in MEASURE 2, and the Wk 52 visit in MEASURE 3 were pooled at the patient level. Exposure-adjusted incidence rates were calculated to account for differences in treatment exposure and analyses included all patients who received ≥1 dose of secukinumab 150 or 300mg. Results: A total of 510 patients were included in the analysis (968.9 patient-years of exposure). The exposure-adjusted AE and SAE rates with secukinumab across the entire safety period were 159.2 and 5.4 per 100 patient-years, respectively. Nasopharyngitis, diarrhoea and headache were the most frequently reported AEs. The incidences of Candida infections, serious infections, inflammatory bowel disease, major adverse cardiac events, neutropenia and uveitis were low and consistent with previous reports over shorter exposure periods 1 (Table) . No cases of suicidal ideation or depression were reported. 
